Overview

Italy is a prominent EU nation with steady demand for drug and biological products. Italian Medicines Agency is responsible to grant approval for the medicinal products before they are marketed in the country which can be obtained by submitting a Marketing Authorization Application (MAA). As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Article 8(3) for New Chemical Entity (NCE) 
  • Article 10 for generic, hybrid and similar biological medicinal products  

Further, the Market Authorization Holder (MAH) has to meet all the requirements listed out by the European Union (EU) and European Economic Area (EEA) considering the UK as a 3rd country post March 30, 2019.

To navigate manufacturers through the Italian Medicine Agency’s compliance requirements, Freyr provides strategic support in handling dossier preparation, submissions and life cycle management for pharmaceutical products. To enable manufacturers make informed choices, Freyr offers Regulatory intelligence for successful market entry.

Freyr Expertise

  • Initial submissions (MAAs) via various procedures- National, Mutual Recognition Procedure (MRP), Decentralized Procedure (DCP) and Centralized Procedure (CP) for innovator, hybrid and generic products 
  • Regulatory consultation and strategic support on submission roadmaps, and procedures 
  • Pre-submission administrative activities such as interaction with Health Authorities (HAs), slot booking for submissions, selection of the RMS and CMS, request to HA to work as RMS 
  • Evaluation of the product and source data from R&D and manufacturing site (executed data) for the EU-specific Regulatory and submission requirements 
  • Compilation and submission of the dossiers to HAs in eCTD format in line with Italian Medicines Agency requirements 
  • Consultation during developments and manufacturing of the medicinal products 
  • Initial submissions for APIs - ASMF/ CEP submissions  
  • Qualified Person (QP), Qualified Person for Pharmacovigilance (QPPV) in EU 
  • Post-approval changes submissions with strategies and compilation/ submission for:   
    • MAH transfers 
    • Post-approval quality change like-  
      • Change in manufacturing site, addition/deletion of the site, Batch size change, changes in manufacturing changes, administrative and labeling changes 
    • Monograph updates i.e. compliance to European pharmacopoeia 
    • Changes in container closure system 
    • Change in primary packaging material supplier 
    • Shelf life extension/reduction 
    • Addition of new supplier for active substance 
    • Inclusion of additional source for starting material for drug substance 
  • Impact analysis of Brexit and submission of the relevant changes to HA(s) like- change in Reference Member State (RMS), changes to MAH, addition/ replacement of the batch release and testing sites, changes to the QP, QPPV and Pharmacovigilance system master file (PSMF) (Article 57 notification) 
  • Life cycle maintenance by submission of renewal applications 
  • Support in handling Italian Medicines Agency’s deficiencies with Regulatory strategy and preparation and submission of the response